Covalent small molecule drug discovery platform
Avila developed a novel chemistry approach ‘Avilomics’ to discover oral small molecule covalent inhibitors of proteases and kinases. Avilomics allows the design of highly specific compounds that irreversibly bind to the protein target to improve therapeutic index and clinical efficacy.
Avila’s most advanced product candidate, AVL-292, a highly selective Btk inhibitor was in Phase I clinical development at the time of its acquisition by Celgene.
CEO Katrine Bosley
Advent Contact Raj Parekh
Advent invested in the Series A in 2007. Avila was acquired by Celgene in 2012 for $925m in cash and milestones.
Exited Investments
Celgene to Acquire Avila Therapeutics
Press Release. Oral Btk inhibitor AVL-292 offers promising potential for treatment of B-cell diseases Avilomics™ Platform enhances drug discovery capabilities SUMMIT, NJ and BEDFORD, MA – January 26, 2012…
Read More
Avila Announces FDA Allowance of Partner Clovis Oncology’s IND Application
Press Release. Avila Announces FDA Allowance of Partner Clovis Oncology’s IND Application for CO-1686, an Oral EGFR Mutant-Selective Inhibitor Triggers $4 Million Milestone Payment to Avila BEDFORD, Mass.--(BUSINESS WIRE)--…
Read More
Avila Therapeutics agreement with NIAID
Press Release. WALTHAM, MA – June 8, 2011 –Avila Therapeutics, Inc. a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced that it has entered…
Read More
Avila Presents New Data on its Novel, Orally-Available Targeted Covalent Drug, AVL-192
Press Release. Covalent Inhibition Achieves Superior Potency Against Drug-Resistant HCV Mutants BOSTON and WALTHAM, MA – Avila Therapeutics™, Inc., a biotechnology company developing novel targeted covalent drugs, presented…
Read More
Avila Initiates Phase 1 Clinical Study of AVL-292, a Targeted Covalent Drug and Novel Potential Treatment for B Cell Cancers and Autoimmune Diseases
Press Release. WALTHAM, Mass. - Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the…
Read More
The Leukemia & Lymphoma Society and Avila Therapeutics Enter Partnership to Accelerate Development of AVL-292 For Patients with Cell B Malignancies
Press Release. White Plains, NY and Waltham, Mass. - The Leukemia & Lymphoma Society (LLS) and Avila Therapeutics, Inc., today announced they have established a collaboration to support development…
Read More
Avila presents data on its novel, orally-available protease inhibitor, AVL-181, demonstrating viral clearance of hepatitis C virus in preclinical models
Press Release. BOSTON & WALTHAM, Mass. - Avila Therapeutics™, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on…
Read More
Avila Therapeutics Announces Agreement with Novartis to Develop Novel Covalent Drug Candidate
Press Release. WALTHAM, Mass.--(BUSINESS WIRE)-- Avila Therapeutics, Inc., an emerging biotechnology company, announced today that it has entered into an option agreement with the Novartis Option Fund focused on…
Read More
Avila Therapeutics, Inc. Closes $30 Million Series B Financing
Press Release. Company to Advance Novel Class of Protein-Silencing Covalent Drugs into Clinic Development WALTHAM, Mass.--(BUSINESS WIRE)-- Avila Therapeutics, Inc., an emerging biotechnology company, announced today that it…
Read More
Avila Therapeutics Appoints Katrine S. Bosley as Company’s First CEO
Press Release. WALTHAM, Mass.--(BUSINESS WIRE)-- Avila Therapeutics, an emerging biopharmaceutical company developing a revolutionary new class of medicines known as covalent drugs, announced today that Katrine S. Bosley has…
Read More
